Diversify Wealth Management LLC Has $1.23 Million Stake in STERIS plc (NYSE:STE)

Diversify Wealth Management LLC raised its position in STERIS plc (NYSE:STE) by 42.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,994 shares of the medical equipment provider’s stock after buying an additional 1,772 shares during the quarter. Diversify Wealth Management LLC’s holdings in STERIS were worth $1,233,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Bleakley Financial Group LLC grew its position in STERIS by 8.7% in the third quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider’s stock valued at $407,000 after acquiring an additional 134 shares during the last quarter. Franklin Resources Inc. grew its holdings in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider’s stock valued at $191,370,000 after purchasing an additional 529,308 shares during the last quarter. Assetmark Inc. grew its holdings in shares of STERIS by 24.6% during the 3rd quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider’s stock valued at $3,252,000 after purchasing an additional 2,647 shares during the last quarter. KBC Group NV increased its position in STERIS by 52.0% during the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider’s stock worth $2,928,000 after purchasing an additional 4,132 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in STERIS in the 3rd quarter valued at approximately $9,949,000. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Stock Down 0.3 %

Shares of NYSE STE opened at $209.50 on Tuesday. STERIS plc has a 52-week low of $197.82 and a 52-week high of $248.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. The company’s 50 day moving average price is $211.79 and its 200-day moving average price is $224.77. The company has a market capitalization of $20.68 billion, a P/E ratio of 47.83 and a beta of 0.84.

STERIS (NYSE:STE) last issued its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business had revenue of $1.33 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the prior year, the firm posted $2.03 earnings per share. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. Equities analysts forecast that STERIS plc will post 9.1 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date was Tuesday, November 19th. STERIS’s payout ratio is 52.05%.

Wall Street Analyst Weigh In

STE has been the topic of a number of research reports. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $230.00 to $260.00 in a research note on Thursday, October 24th. Stephens reaffirmed an “overweight” rating and issued a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a research report on Monday, November 18th. Finally, StockNews.com lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $262.50.

Insider Activity

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction on Monday, November 25th. The shares were sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.14% of the stock is currently owned by company insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.